T Cell News and Research

Latest T Cell News and Research

T-cell apoptosis linked to poor prognosis among COVID-19 patients

T-cell apoptosis linked to poor prognosis among COVID-19 patients

26 Jan 2022
Study shows enduring T-cell immunity up to at least 1-year after SARS-CoV-2 infection

Study shows enduring T-cell immunity up to at least 1-year after SARS-CoV-2 infection

26 Jan 2022
Study provides a new treatment option for patients with relapsed B-cell lymphoma

Study provides a new treatment option for patients with relapsed B-cell lymphoma

26 Jan 2022
Third dose of BNT162b2 vaccine protects against Omicron hospitalizations

Third dose of BNT162b2 vaccine protects against Omicron hospitalizations

25 Jan 2022
Evaluation of cross-reactive T cell responses between SARS-CoV-2 and common-cold human coronaviruses

Evaluation of cross-reactive T cell responses between SARS-CoV-2 and common-cold human coronaviruses

25 Jan 2022
Study finds stable T-Cell response against Omicron after mRNA booster vaccination

Study finds stable T-Cell response against Omicron after mRNA booster vaccination

24 Jan 2022
Genetic marker linked to higher risk of death in COVID-19 patients

Genetic marker linked to higher risk of death in COVID-19 patients

23 Jan 2022
Novel SARS-CoV-2 mutations reported in chronic HIV patients

Novel SARS-CoV-2 mutations reported in chronic HIV patients

23 Jan 2022
Robust BNT162b2 vaccine-induced B and T-cell immunity against early SARS-CoV-2 variants

Robust BNT162b2 vaccine-induced B and T-cell immunity against early SARS-CoV-2 variants

23 Jan 2022
Research shows benefits of hybrid immunity to SARS-CoV-2

Research shows benefits of hybrid immunity to SARS-CoV-2

20 Jan 2022
Study suggests myeloid cell dysregulation is a driver of COVID-19 severity

Study suggests myeloid cell dysregulation is a driver of COVID-19 severity

17 Jan 2022
Efficacy and safety of mRNA-based SARS-CoV-2 vaccination in immuno-compromised subjects

Efficacy and safety of mRNA-based SARS-CoV-2 vaccination in immuno-compromised subjects

17 Jan 2022
Dexamethasone shown to upregulate innate and adaptive immune responses in COVID-19 acute respiratory distress syndrome patients

Dexamethasone shown to upregulate innate and adaptive immune responses in COVID-19 acute respiratory distress syndrome patients

17 Jan 2022
Naïve T cells suggested as critical to low mortality of children with COVID-19

Naïve T cells suggested as critical to low mortality of children with COVID-19

14 Jan 2022
Insignificant homology of SARS-CoV-2 spike sequences to myocarditis-associated antigens

Insignificant homology of SARS-CoV-2 spike sequences to myocarditis-associated antigens

13 Jan 2022
Moffitt experts provide insight on the role of B cell immunity in endometrial cancer

Moffitt experts provide insight on the role of B cell immunity in endometrial cancer

13 Jan 2022
Lack of evidence cross-reactive adaptive immune response is mechanism underlying COVID vaccine-induced myocarditis

Lack of evidence cross-reactive adaptive immune response is mechanism underlying COVID vaccine-induced myocarditis

12 Jan 2022
Cellular and humoral response to SARS-CoV-2 in multiple sclerosis patients using disease-modifying therapies

Cellular and humoral response to SARS-CoV-2 in multiple sclerosis patients using disease-modifying therapies

12 Jan 2022
Third dose of mRNA COVID vaccine induces strong immunity in older adults

Third dose of mRNA COVID vaccine induces strong immunity in older adults

11 Jan 2022
Phase 1 clinical trial shows the safety, feasibility of CAR-M cell therapy for solid tumors

Phase 1 clinical trial shows the safety, feasibility of CAR-M cell therapy for solid tumors

11 Jan 2022

Newsletters you may be interested in

See all Newsletters »

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback